Selective inhibition of HDAC6 sensitizes cutaneous T‑cell lymphoma to PI3K inhibitors

Histone deacetylase (HDAC) inhibitors, approved for the treatment of cutaneous T-cell lymphoma (CTCL), are non-selective agents associated with an unsatisfactory response and considerable side-effects. Targeting single HDAC isoforms is considered to provide novel therapeutic options. HDAC6 is overex...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncology letters 2020-07, Vol.20 (1), p.533-540
Hauptverfasser:	Bobrowicz, Malgorzata, Slusarczyk, Aleksander, Domagala, Joanna, Dwojak, Michal, Ignatova, Desislava, Chang, Yun-Tsan, Iselin, Christoph, Miazek-Zapala, Nina, Marhelava, Katsiaryna, Guenova, Emmanuella, Winiarska, Magdalena
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Clinical trials Cloning Drug therapy Ethylenediaminetetraacetic acid Flow cytometry Genetic engineering Health aspects Kinases Lymphoma Medical prognosis Medical research Medicine, Experimental Non-Hodgkin's lymphomas Patients Pharmaceutical industry Proteins Signal transduction T cells Vorinostat
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!